Market closed
CorMedix/$CRMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CorMedix
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Ticker
$CRMD
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
65
Website
CorMedix Metrics
BasicAdvanced
$490M
-
-$0.30
1.57
-
Price and volume
Market cap
$490M
Beta
1.57
52-week high
$13.09
52-week low
$3.61
Average daily volume
2M
Financial strength
Current ratio
3.386
Quick ratio
3.054
Long term debt to equity
0.412
Total debt to equity
0.611
Interest coverage (TTM)
-614.10%
Management effectiveness
Return on assets (TTM)
-13.91%
Return on equity (TTM)
-23.17%
Valuation
Price to revenue (TTM)
10.184
Price to book
5.72
Price to tangible book (TTM)
5.85
Price to free cash flow (TTM)
-8.727
Growth
Earnings per share change (TTM)
-66.54%
3-year revenue growth (CAGR)
510.62%
3-year earnings per share growth (CAGR)
-25.91%
What the Analysts think about CorMedix
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for CorMedix stock.
CorMedix Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CorMedix Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CorMedix News
AllArticlesVideos
Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance
GlobeNewsWire·1 week ago
CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewsWire·2 weeks ago
An Investigation Has Commenced on Behalf of CorMedix Inc. Shareholders. Contact Levi & Korsinsky to Discuss your CRMD Losses.
Accesswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for CorMedix stock?
CorMedix (CRMD) has a market cap of $490M as of April 18, 2025.
What is the P/E ratio for CorMedix stock?
The price to earnings (P/E) ratio for CorMedix (CRMD) stock is 0 as of April 18, 2025.
Does CorMedix stock pay dividends?
No, CorMedix (CRMD) stock does not pay dividends to its shareholders as of April 18, 2025.
When is the next CorMedix dividend payment date?
CorMedix (CRMD) stock does not pay dividends to its shareholders.
What is the beta indicator for CorMedix?
CorMedix (CRMD) has a beta rating of 1.57. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.